Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics
Wong, S.-Y.; Gold, S.; Accorsi, E. K.; Cowger, T. L.; Wiseman, D.; Navalurkar, R.; Dixon, R.; Helmus, D. S.; CiTI Study Group, ; Firpo-Betancourt, A.; Mendu, D. R.; Zolla-Pazner, S.; Cadwell, K.; Colombel, J.-F.
Show abstract
Patients with immune-mediated inflammatory diseases (IMIDs) and acquired and genetic immunodeficiencies receiving therapeutic infusions are considered high risk for SARS-CoV-2 infection. However, the seroprevalance in this group and the safety of routine administrations at outpatient infusion centers are unknown. To determine the infection rate and clinical-social factors related to SARS-CoV-2 in asymptomatic patients with IMIDs and immunodeficiencies receiving routine non-cancer therapeutic infusions, we conducted a seroprevalence study at our outpatient infusion center. We report the first prospective SARS-CoV-2 sero-surveillance of 444 IBD/IMID, immunodeficiency, and immune competent patients at an outpatient infusion center in the U.S. showing lower seroprevalence in patients compared with the general population and provide clinical and social characteristics associated with seroprevalence in this group. These data suggest that patients can safely continue infusions at outpatient centers.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease 95%
- Seroconversion following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients 94%
- Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease 94%
Similar papers in this journal
- Effectiveness and Safety of Combining Tofacitinib with a Biologic in Patients with Refractory Inflammatory Bowel Diseases 94%
- Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis 94%
- Adverse Events Following SARS-CoV-2 mRNA Vaccination Among Patients with Inflammatory Bowel Disease 93%
Similar papers in this journal
- Optimising Early Management of Acute Severe Ulcerative Colitis in the Biologics Era: Admission Model for Intensification of Therapy in Acute Severe Colitis (ADMIT–ASC) 93%
- Maintenance therapy with infliximab or vedolizumab in inflammatory bowel disease is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic 92%
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines 92%
Similar papers in this journal
- Gut microbiota alterations in patients with persistent respiratory dysfunction three months after severe COVID-19 90%
- Research Letter: Incidence of SARS-CoV-2 infection among unvaccinated US adults during the Omicron wave 89%
- Understanding the patterns of repeated testing for COVID-19: Association with patient characteristics and outcomes 87%
Similar papers in this journal
- Linking Gene Expression to Clinical Outcomes in Pediatric Crohn's Disease Using Machine Learning 93%
- Association of Chronic Acid Suppression and Social Determinants of Health with COVID-19 Infection 91%
- Characteristics and outcomes of clinically diagnosed RT-PCR swab negative COVID-19: a retrospective cohort study 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.